MaxCyte, Inc. (MXCT), a leader in cell engineering, announced on Monday its anticipation of fourth-quarter core revenue between $8.3 million and $8.5 million, a rise from the $7.2 million recorded during the same period last year. For the entire year, initial estimates suggest core revenue ranging from $32.2 million to $32.4 million, surpassing last year's $29.8 million.
Maher Masoud, CEO of MaxCyte, commented, "As the cell therapy industry progresses into 2025, the business landscape shows signs of improvement. We are optimistic about MaxCyte's future prospects. In 2024, we expanded our SPL customer base by six, supported the commercial introduction of the FDA-approved first non-viral gene-edited cell therapy product, and achieved robust revenue growth alongside enhanced operational efficiency."
The company plans to disclose its full-year SPL program-related revenue and total revenue figures in March.
The material has been provided by InstaForex Company - www.instaforex.com
Maher Masoud, CEO of MaxCyte, commented, "As the cell therapy industry progresses into 2025, the business landscape shows signs of improvement. We are optimistic about MaxCyte's future prospects. In 2024, we expanded our SPL customer base by six, supported the commercial introduction of the FDA-approved first non-viral gene-edited cell therapy product, and achieved robust revenue growth alongside enhanced operational efficiency."
The company plans to disclose its full-year SPL program-related revenue and total revenue figures in March.
The material has been provided by InstaForex Company - www.instaforex.com